

Journal Pre-proof

Different instrumental approaches to understand the chitosan coated niosomes/mucin interaction

Federica Rinaldi, Patrizia Nadia Hanieh, Anna Imbriano, Daniele Passeri, Elena Del Favero, Marco Rossi, Carlotta Marianecchi, Simone De Panfilis, Maria Carafa



PII: S1773-2247(19)31336-X

DOI: <https://doi.org/10.1016/j.jddst.2019.101339>

Reference: JDDST 101339

To appear in: *Journal of Drug Delivery Science and Technology*

Received Date: 5 September 2019

Revised Date: 15 October 2019





Accepted Date: 19 October 2019

Please cite this article as: F. Rinaldi, P.N. Hanieh, A. Imbriano, D. Passeri, E. Del Favero, M. Rossi, C. Marianecchi, S. De Panfilis, M. Carafa, Different instrumental approaches to understand the chitosan coated niosomes/mucin interaction, *Journal of Drug Delivery Science and Technology* (2019), doi: <https://doi.org/10.1016/j.jddst.2019.101339>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2019 Published by Elsevier B.V.

NIOSOMES-MUCIN INTERACTION



1 **Different instrumental approaches to understand the chitosan coated**
2 **niosomes/mucin interaction.**

3 Federica Rinaldi^a, Patrizia Nadia Hanieh^b, Anna Imbriano^b, Daniele Passeri^c, Elena
4 Del Favero^d, Marco Rossi^c, Carlotta Marianecchi^{b*}, Simone De Panfilis^a, Maria
5 Carafa^b

6 ^a Center for Life Nano Science@Sapienza, Istituto Italiano di Tecnologia (ITT), Viale
7 Regina Elena 291, 00161 Rome, Italy; federica.rinaldi@iit.it, simone.depanfilis@iit.it.

8 ^b Department of Drug Chemistry and Technology, Sapienza University of Rome,
9 P.zzle A. Moro 5, 00185 Roma, Italy; patrizianadia.hanieh@uniroma1.it;
10 anna.imbriano@uniroma1.it; carlotta.marianecchi@uniroma1.it;
11 maria.carafa@uniroma1.it.

12 ^c Department of Basic and Applied Sciences for Engineering, Sapienza University of
13 Rome, Via A. Scarpa 14, 00161 Rome, Italy; daniele.passeri@uniroma1.it;
14 marco.rossi@uniroma1.it.

15 ^d Department of Medical Biotechnology and Translational Medicine, University of
16 Milan, V.le F.lli Cervi 93, 20090 Segrate, Italy; elena.delfavero@unimi.it.

17

18

19

20

21

22 * Corresponding author: Carlotta Marianecchi, Department of Drug Chemistry and
23 Technologies, Sapienza University of Rome, Piazzale A. Moro 5, Rome 00185, Italy.
24 E-mail address: carlotta.marianecchi@uniroma1.it

25

26

27

28

29

30

Abstract

Span-20 non-ionic surfactant vesicles (niosomes), designed for future applications in brain drug delivery through intranasal route, are prepared and coated with chitosan glutamate, a mucoadhesive agent specifically proposed for brain delivery and for an optimal interaction with nasal mucin, with the aim to promote the vesicles residence time in the nasal cavity. The understanding of the interaction between chitosan coated niosomes with mucin is of great relevance as it can influence their in vivo distribution and physiological behaviour. Complementary and different techniques are then used in a non-conventional combined approach to study this phenomenon. The integrated use of dynamic light scattering (DLS), fluorimetric and spectrophotometric assays, small-angle X-ray scattering (SAXS), atomic force microscopy (AFM) and high speed brightfield microscopy (BFM) allows to shed new light on the physico-chemical behaviour of the mucin-niosomes system, addressing this complex phenomenon by different perspectives.

Keywords

Niosomes, mucoadhesion, AFM, SAXS, BFM and DLS.

58 1. Introduction

59 Every technique possesses particular features that can be combined or compared to
60 others to address the overall nanocarriers properties.

61 In a classical characterization approach, a specific technique is applied to study a
62 distinct parameter: e.g. Small angle x-ray scattering (SAXS) [1] is used to determine
63 with high accuracy size and bilayer features of vesicles; atomic force microscopy
64 (AFM) [2] is applied to provide textural information on nanocarriers; high speed
65 brightfield microscopy (BFM) [3, 4] is commonly used to study cell-nanocarrier
66 interactions; dynamic light scattering (DLS) is able to provide dimensions and ζ -
67 potentials of particles dispersed in a fluid [5]. Furthermore fluorimetric and
68 spectrophotometric techniques are usually applied in pharmaceuticals to provide
69 probe/drug quantitative analyses, as in release studies. Here, in a less conventional
70 approach, all these techniques are used in a combined way, out of their usual
71 application field, to study the interaction between chitosan coated niosomes and
72 mucin.

73 Niosomes (non-ionic surfactant vesicles) are vesicular systems with nanometric
74 dimensions, characterized by an aqueous core and lipophilic bilayer. They are
75 composed by a non-ionic surfactant (e.g. Span 20) coupled together with cholesterol.
76 They are able to entrap and deliver both lipophilic and hydrophilic drugs or probes
77 and the potential to modulate both their pharmacokinetic and pharmacodynamic
78 profiles, thereby enhancing their therapeutic index. Vesicles increase drug in vivo
79 stability, extend its blood circulation time, and allow controlled drug release obtaining
80 a specific biodistribution of drugs reducing side effects. Although only a few niosomal
81 formulations are in clinical trials, and no formulations are in the commercial market,
82 their several advantages, including also low toxicity, high chemical stability, and
83 lower manufacturing cost, provided the opportunity to develop a niosomal medicine
84 product for brain delivery.

85 To obtain niosomal formulations able to carry out nose-to-brain delivery, some
86 factors must be taken in account. In particular, to enhance the niosomal residence
87 time in nasal cavity, a mucoadhesive agent must be added. Chitosan is a
88 biodegradable and bioadhesive polymer able to interact with the mucin in nasal
89 cavity thanks to electrostatic interactions. Chitosan prolongs residence time in the
90 nasal cavity of drugs and/or formulations, allowing drug delivery systems to promote

91 drug absorption In recent studies chitosan glutamate (CG) is also proposed as a
92 better mucoadhesive agent than chitosan or chitosan salts [6-8]. To this aim, CG is
93 used to coat niosomes, obtaining CG-niosome complexes, to confer mucoadhesive
94 properties to the formulation, able to be successfully used for intranasal applications.
95 Of course, the physical-chemical properties of these CG-niosome complexes affect
96 their in vivo distribution and physiological behaviour and must be properly
97 characterized to better understand their efficacy as intranasal drug carriers.

98 The aim of this work is to use different techniques [9] to study the interaction
99 between mucin and chitosan-glutamate-niosomes loaded with model drug (CG-
100 NioP), to this aim, DLS [10], fluorometric and spectrophotometric assays, SAXS,
101 AFM and BFM have been employed.

102

103 **2. Materials and Methods**

104

105 *2.1. Materials*

106 HEPES salt (Sodium 2-(4-(2-hydroxyethyl) piperazin-1-yl) ethanesulfonate),
107 cholesterol, Sephadex G75, model drug (pentamidine isethionate), pyrene,
108 mucin from porcine stomach type II powder, Span 20 (Sorbitan monolaurate),
109 chitosan medium molecular weight powder (C) and sodium hydroxide were
110 purchased from Sigma-Aldrich (Milan, Italy). L-Glutamic acid (G) was supplied by
111 PanReac Applichem (Milan, Italy). All other products and reagents were of
112 analytical grade.

113

114 *2.2. Methods*

115 *2.2.1. Niosome Preparation and Purification*

116 Niosomes were prepared using thin film hydration method [8, 10]. Span 20 (15
117 mM) and cholesterol (15 mM) were dissolved in organic solvent mixture
118 (chloroform/methanol 3:1 v/v). The solvent was evaporated using rotary
119 evaporator (VV2000, Heidolph, Schwabach, Germany) to form a thin “film” at the
120 temperature of 60 °C. The lipophilic components, such as Pyrene, were
121 solubilized with organic solvents together with cholesterol and surfactant, while
122 the hydrophilic components, such the model drug, were added during the
123 hydration step. In particular, the film was hydrated using 5 mL of model drug
124 solution (0,5 mg/mL in HEPES buffer 0.01 M, pH 7.4), vortexed and sonicated at

125 60 °C and 18% amplitude for 15 min using ultrasonic microprobe (Vibra-Cell
126 VCX-400, Sonics & Materials, Newtown, CT, USA). The unilamellar vesicle
127 suspension was purified by gel filtration chromatography using Sephadex G75
128 (glass column of 50 × 1.2 cm) with HEPES buffer as the eluent. The obtained
129 purified vesicles were filtrated by using cellulose filters with pore diameter of 1.2
130 µm, to purify the niosomal suspension and obtain desired dimensions.

131

132 *2.2.2. Preparation of Chitosan Glutamate-Coated Niosomes with model drug*

133 Chitosan glutamate solution was prepared by dissolving C (1 mg) and G (0.82
134 mg) in acetate buffer (0.2 M, pH 4.4) up to a final concentration of 0.05 mg/mL
135 [11]. The obtained solution was stirred overnight [12]. CG coating of model drug
136 loaded niosomes (NioP) was obtained by adding a CG solution to vesicular
137 suspension into a 1:1 ratio [13]. The obtained suspension was stirred for 1 h at
138 room temperature to achieve CG-coated model drug niosomes (CG-NioP). pH
139 values were measured and confirmed for all formulations to match a suitable pH
140 for nasal administration ($3.5 < \text{pH} < 6.4$).

141

142

143 *2.2.3. Preparation of Mucin Solution and Mucoadhesive Studies*

144 Mucin powder was dissolved in HEPES buffer to produce a mucin solution (2
145 mg/mL, pH 6) and stirred overnight at 34°C [14]. Specific parameters, including
146 temperature (30°C), concentration of mucin (2 mg/mL) and pH value (6.3–6.7),
147 were analysed in the mucoadhesive study to mimic the conditions in the nasal
148 mucosal site [15]. Mucin solutions (2 mg/mL) were mixed with CG-NioP
149 suspensions (1:1 ratio) and incubated at 30°C [15, 16]. The concentration of
150 mucin solutions employed in this study was modified to obtain optimal pH value
151 (6.3–6.7) [15, 17].

152

153 *2.2.4. DLS*

154 Uncoated niosomes with model drug, CG-NioP and mixture of CG-NioP with
155 mucin (CG-NioP-M) were analysed and their particle diameter, polydispersity
156 index (PDI) and ζ -potential were measured in HEPES buffer by dynamic light
157 scattering using a Zetasizer (Nano ZS90, Malvern, UK) (n= 3 repeated

158 measurements for each sample) [10]. Particle size and ζ -potential were
159 measured at 0, 5, 10, and 15 min, to determine the time-course of uncoated and
160 coated niosome-mucin interaction and the stability of the obtained complex.
161 Results related to the data collected at 15 min were considered (in order to
162 mimic the *in vivo* interaction time of intranasal administration) even when the
163 interaction was already almost complete after only 5 min. Mucoadhesive
164 measurements were carried out expressing particle dimension as hydrodynamic
165 diameter and evaluating also the different curves related to size distribution by
166 intensity to better appreciate the formation of complex between CG-NioP and
167 mucin, in order to avoid artefacts due to the potential mucin aggregates.

168

169 *2.2.5. Fluorimetry*

170 Interactions by CG-NioP and mucin were also evaluated by fluorescence
171 turbidity measurements using luminescence spectrometer (LS5013,
172 PerkinElmer, Waltham, MA, USA) at Ex/Em 600/600 nm [16]. Bilayer
173 characterization was carried out on NioP, CG-NioP and CG-NioP-M. Due to its
174 lateral diffusion within the bilayer, pyrene provides a wider picture of the bilayer
175 characteristics, such as microviscosity and polarity [18]. By fluorescent
176 techniques the behaviour inside bilayer and the expected interaction between
177 mucin and the bilayer were evaluated. Pyrene loaded niosomes were prepared
178 by adding pyrene (4 mM) with other vesicle components (same preparation
179 method as above). The lateral distribution and the mobility of membrane
180 compounds can be studied by fluorescence measurements. Pyrene is a
181 fluorescence probe; whose monomer exhibited a spectrum characterized with five
182 emission peaks (from I₁ to I₅) and excimer has only one peak (I_E). Pyrene can
183 form intramolecular excimer based on the viscosity of the probe
184 microenvironment [19]. The fluorescence signals emitted by pyrene loaded
185 niosomal suspension were studied by an emission spectrum ($\lambda = 350\text{--}550$ nm)
186 using and Ex= 330 nm by a luminescence spectrometer (LS5013, PerkinElmer)
187 [20].

188

189 *2.2.6. Spectrophotometry*

190 a) Mucoadhesive strength was determined by the method proposed by Sandri et
191 al. [21] The percent binding efficiency of niosomes to mucin was determined by

192 mixing 1 ml of porcine mucin suspension (2 mg/ml in Hepes buffer) with the
193 same volume of CG-NioP or NioP. The mucin alone and then the mixture with
194 niosomal suspensions were then centrifuged at 18000 rpm for 30 min at
195 temperature of 4°C. The concentration of free mucin in the supernatant was
196 determined at 255 nm using UV spectrophotometer (Perkin-Elmer lambda 25
197 UV/Vis). The mucin binding efficiency of CG-NioP was calculated from the
198 following equation:

199

$$200 \quad \text{Mucin binding efficiency (\%)} = \frac{\text{Total mucin} - \text{Free mucin}}{\text{Total mucin}} \times 100 \quad (1)$$

201

202 b) Aliquots of CG-NioP, NioP and CG were mixed with mucin (1:1 in volume).
203 The effective absorbance (A) of the samples, operating at $\lambda = 500\text{nm}$, was
204 compared to the theoretical absorbance (A_{theor}) calculated by adding the
205 individual absorbance values of the mucin and each sample suspension (CG-
206 NioP, NioP and CG). The difference in absorption ($\Delta A = A - A_{\text{theor}}$) was taken as
207 a measure of the interaction between mucin and CG-NioP, NioP or CG, namely
208 $\Delta A \approx 0$ if no interaction occurs, while if $\Delta A > 0$, a strong interaction between
209 mucin and the analysed samples was inferred.

210

211 2.2.7. SAXS

212 SAXS experiments were carried out at the European Synchrotron Radiation
213 Facility (ESRF, Grenoble, France) to obtain information on the internal structure
214 of formulations for drug delivery [5, 21]. In the case of SAXS the intensity decay
215 behaviour as a function of momentum transfer q ($q = (4\pi/\lambda) \sin(\theta/2)$, being θ the
216 scattering angle) can provide knowledge on the structure of particles in solution
217 down to the nm length scale. Measurements were acquired at the high-brilliance
218 beamline ID02, with two sample-detector distances, in the region of momentum
219 transfer $0.017\text{nm}^{-1} \leq q \leq 5\text{nm}^{-1}$. Samples were inserted in 2mm capillaries (KI-
220 beam, ENKI, Concesio, Italy) and placed horizontally onto a thermostated
221 sample holder ($T=25 \pm 0.1$ °C). Very shorts frames were collected (exposure
222 time 0.1 s) and checked for effects induced by radiation damage before being
223 averaged. After radial integration and background subtraction, the SAXS profiles
224 report the scattered radiation intensity as a function of momentum transfer, q .

225

226 *2.2.8. AFM*

227 Atomic force microscopy (AFM) topographical characterization were carried out
 228 using a standard AFM setup (Dimension Icon, Bruker Inc. in ‘soft tapping’ mode)
 229 equipped with standard silicon cantilevers (OTESPA, Bruker Inc.). A drop of
 230 solution was deposited on a 111 single-crystal silicon waiting a few minutes to
 231 allow some vesicles to adhere to the substrate. Eventually, the drop was drawn
 232 in order to prevent the deposition of excessive material, which could lead to the
 233 formation of a continuous film instead of isolated vesicles. A few minutes were
 234 further waited to allow an (incomplete) evaporation of the solvent at room
 235 conditions. Images were collected near the edge of the drops to avoid regions
 236 with too dense material on the surface.

237 In order to perform statistics on the size of the vesicles, AFM images were
 238 analysed using the ‘Particle Analysis’ tool of the instrument. For both the CG-
 239 NioP and CG-NioP-M samples, 20 different vesicles were analysed. The
 240 mechanisms of adsorption of vesicles on the substrate surface as well as the
 241 possible partial dehydration make the vesicles lose their original spherical shape
 242 resulting in spherical caps on the flat substrate surface [22], as depicted in the
 243 inset of Fig. 4(e). Each vesicle was analysed by evaluating the diameter D_{AFM}
 244 and the height h_{AFM} measured from the AFM morphology. Assuming that the
 245 adsorption and partial dehydration process modify the volume of the vesicle but
 246 not the surface area, the latter can be evaluated as the sum of the areas of the
 247 surface of the spherical cap $A_{cap} = \pi(D_{AFM}^2/4 + h_{AFM}^2)$ and of the base circle
 248 $A_{base} = \pi D_{AFM}^2/4$. Therefore, the equivalent diameter D_{eq} of a sphere with the
 249 same surface is given by:

250

$$251 \quad D_{eq} = \sqrt{\frac{D_{AFM}^2}{2} + h_{AFM}^2} \quad (2)$$

252

253 *2.2.9. Brightfield microscopy*

254 Samples of diluted CG-NioP and CG-NioP-M were held at room temperature in a
 255 4-well Ibidi μ -slide, with a glass bottom especially conceived for microscopy
 256 purposes. The slide was adjusted into a motorized x-y translation stage, held in
 257 an Olympus IX73 inverted microscope, and illuminated by a conventional 100 W

258 halogen lamp through the condenser (N.A. 0.55). Transmitted light was collected
259 by an UPLSAPO 100XO super-apochromat immersion oil objective (N.A. 1.4).
260 Suitable optic elements projected the illuminated field of view onto a high-
261 resolution high sensitivity CoolSNAP™ MYO CCD camera by Photometrics
262 (1940x1460 imaging array, 4.54x4.54 μm pixel size, 20 MHz readout and 14 bit
263 dynamic range) connected with the control workstation. The optical magnification
264 converted the CCD pixel size at the imaging plane down to 45 nm.

265 The entire imaging setup, including the microscope, sample positioning,
266 illumination and detection, was controlled via MetaMorph™ microscopy
267 automation and image analysis software by Molecular Devices. Images of both
268 the two samples were collected in streaming mode, at 36 fps, each image lasting
269 10 ms, for a total stream length of 1000 images, and stored as single timescan
270 TIF files.

271 The time-stack stream files were processed via Fiji software bundle [23]. To
272 emphasize the shape of the floating niosomes, time average images were
273 subtracted to the respective time-stack streams. The particles traces appearing
274 and disappearing on the focal plane were then isolated and the intensity profile
275 measured along the trace. These curves were fitted with Lorentzians, a
276 convenient approximation of the convolution between a hemisphere, the
277 niosomes, and the overall microscope point spread function resulting from the
278 combination of the condenser illumination and the objective collection. The
279 profiles with the highest intensity and smaller full width at half maximum (FWHM)
280 as obtained by the fit were then retained. More than 20 FWHM data were
281 accumulated per each sample.

282

283 **3. Results and discussion**

284 Different perspectives to a given phenomenon help in sharpening the
285 resolution in the parameter space. This approach is applied in characterizing
286 the CG-mucin-niosomes complexes. The aim of the present paper is to obtain
287 a unified description of chitosan coated niosomes/mucin interaction, taking
288 advantage of the characteristics of each technique. This approach is able to
289 highlight the same phenomenon but from different points of view and to give
290 an overall idea of the final object.

291

292 **3.1. DLS**

293 The niosomal samples were tested for their size, ζ -potential, and
 294 polydispersity index (PDI) using DLS measurements. CG-NioP niosomes bear
 295 negative surface charge. This was due to the presence of the Span 20
 296 surfactant and of a reduced amount of CG, which is insufficient to grant a
 297 complete charge inversion on the vesicles, but that allows for a significant
 298 interaction with the mucin. Higher amount of CG, would indeed produce
 299 structures with different chemical-physical characteristics [11].

300 The size of empty CG-Nio is small (~ 170 nm), and it increases in presence of model
 301 drug, but it does remain small enough for an efficient intranasal administration [1].

302 The interaction between mucin (the main component in mucus) and CG-NioP was
 303 evaluated determining the differences in size and surface charge before and after
 304 addition of mucin. The hydrodynamic diameter, ζ -potential, pH, and turbidity values
 305 listed in Tab. 1 were all compatible with the same mucin-CG-NioP interaction
 306 scheme. The values related to the CG-NioP-M that were always in between the
 307 mucin and CG-NioP samples, while there were no evidences of mucin interacting
 308 with uncoated samples (data not shown).

309

310

Sample	Vesicles diameter (10^2 nm)			ζ -Potential (mV)	PDI	Turbidity (arb. units)	pH
	DLS	AFM	BFM	DLS	DLS	Fluorimetry	
CG-NioP	2.0 ± 0.1	2.1 ± 0.3	2.2 ± 0.3	-46.3 ± 0.1	0.1	440.1	6.5
CG-NioP-M	2.6 ± 0.1	3.2 ± 0.1	3.0 ± 0.5	-30.0 ± 2.0	0.3	322.9	6.3
Mucin	16.2 ± 0.6		-	-15.6 ± 0.4	-	257.3	6.1

311


312 **Table 1.** Characteristics of CG-NioP, CG-NioP-M and Mucin. Vesicles diameter and
 313 ζ -Potential are expressed as mean \pm standard deviation of three measurements.
 314 BFM data refer to deconvoluted average particle diameters.

315

316

317 The interaction between mucin and chitosan was a “non-specific” one, that includes

318 also a physical entanglement between the polymer and mucus layer, although CG-
 319 NioP bear negative ζ -potential values [24]. The PDI values of the mixtures were
 320 significantly higher than CG-NioP, due to the polydisperse system of the mixture,
 321 possibly as a consequence of the disordered assembly of the mucin layers onto the
 322 original niosomes surfaces. Size distribution by intensity curves for mucin alone, CG-
 323 NioP and CG-NioP-M were shown in Fig. 1 panel a. The bell-shaped size distribution
 324 curve of CG-NioP-M was located between the curves of mucin alone and CG-NioP,
 325 as a result of the adhesion of mucin on coated niosome samples; this behaviour
 326 suggests the successful formation of bigger aggregates and a complete mucin- CG-
 327 NioP due to the formation of the narrow curve of CG-NioP-M and the total
 328 disappearance of the mucin curve.
 329



330
 331 **Figure 1.** Panel a: Size distribution by intensity of CG-NioP (red), CG-NioP-M
 332 mixture (blue) and mucin solution (green). Panel b: Interaction kinetic and in vitro
 333 stability of complexes CG-NioP by DLS measurements.
 334

335
 336 To investigate the interaction kinetic of CG-NioP and mucin in terms of size and ζ -
 337 potential, measurements were carried out at different time intervals. In Fig. 1 panel b,
 338 the temporal evolution of these quantities as derived by DLS was shown. Already
 339 after 5 min, the particle size and the ζ -potential both increase, respect those reported
 340 in Table 1, up to a time average value around which the following respective
 341 measurements oscillate. It can be supposed that the interaction occurs immediately,
 342 and the obtained complexes remain stable during the time interval observed; this

343 aspect is important because it could predict a possible *in vivo* sample stability.


344

345 3.2. Spectrophotometry

346 The interaction between mucin and niosomes was evaluated by measuring the UV
 347 spectra of the supernatant after incubation and centrifugation. In Fig. 2: panel a the
 348 percentage of mucin in the precipitate is reported, measured as the difference
 349 between the total amount of mucin and the free mucin present in the supernatant.
 350 When only mucin was present in the suspension, the 50% precipitates after
 351 centrifugation, while when NioP were included in the solution, a little increase in the
 352 precipitated percent was noted, probably as a consequence of a mechanical
 353 interaction between niosomes and mucin. An almost complete precipitation of mucin
 354 occurred when CG-NioP were present in the suspension, because of the “non-
 355 specific” mucin interaction and a physical entanglement between the polymer and
 356 the mucus layer.

357

358



359

360 **Figure 2.** Panel a: Mucoadhesive efficiency of niosome: mucin interaction evaluating
 361 the percent of precipitated mucin. Panel b: ΔA values as a measure of effectiveness
 362 interaction of CG-M, NioP-M and CG-NioP-M.

363

364

365 This technique is also useful to evaluate the mucoadhesion performance of CG-NioP
 366 expressed as difference in absorption (ΔA) (Fig. 2: panel b). The values obtained by
 367 mixing pure CG and mucin were reported.


368 This differential absorbance ΔA was able to provide information about the relevance
369 of chitosan-mucin interaction in the overall process. The interaction between CG and
370 mucin, considered as a reference for the purpose of this experiment, gives
371 information about the maximum achievable interaction. This is the result of a balance
372 between the interaction of anionic charges of mucin with positive ones on the
373 polymeric chain and the competitive effect of ions and high ionic strength in the
374 suspensions. After the addition of mucin to NioP, no difference in absorption
375 occurred, due to the absence of positive charges on the niosomal surface. CG-NioP
376 presented a value of $\Delta A > 0$, higher respect to our control that is NioP with mucin.
377 Coated niosomes showed in fact a value of $\Delta A > 0$ comparable to the value obtained
378 with CG-M, that were related to an interaction with mucin. In presence of CG, the
379 niosomal adhesion performance was enhanced because of the best mucoadhesive
380 properties due to the exposed charged groups on niosomal surface to external
381 interactions. The CG present in the suspension was not completely free, as it was in
382 the control suspension, because it was partially involved in the niosomal surface
383 interaction and its ability to interact with mucin was depleted.

384

385 *3.3. Fluorimetry*

386 Bilayer characterization was carried out on NioP, CG-NioP and the mixture obtained
387 after adding CG-NioP with mucin, respectively. Pyrene, a lipophilic probe, was
388 located within the bilayer, and provides different information due to its different
389 conformations inside the bilayer: monomers and excimers come up with different
390 fluorescent spectra as depicted in Fig. 3.

391



392

393 **Figure 3.** Pyrene emission spectrum (Ex: 330 nm; $I_1= 373$ nm; $I_3= 385$ nm; $I_E= 464$
 394 nm) of samples: NioP (green), CG-NioP (red) and CG-NioP-M (blue).

395

396

397 Pyrene monomer exhibited a spectrum characterized with five emission peaks (from
 398 *I1* to *I5*) and pyrene excimer has only one peak (*IE*). The pyrene spectrum in NioP, in
 399 the absence of CG, shows peaks related to both monomer and excimer geometries,
 400 while when CG was added to the formulation, the disappearance of the excimer
 401 peak was observed. This was related not only to the external coating, but also to
 402 different interactions that might be responsible of a change in bilayer behaviour. The
 403 further addition of mucin produces no dramatic change in the CG-NioP bilayer, as
 404 also indicated by the SAXS measurements discussed below. According to DLS data,
 405 the interaction between coated niosomes and mucin was responsible only for a
 406 dimensional increase of the complexes. The alternative and non conventional use of
 407 pyrene probe confirmed the external interaction between CG-NioP and mucin with
 408 no bilayer perturbation according to SAXS results.

409


410 3.4. AFM

411 In Fig. 4, the morphology of the CG-NioP and CG-NioP-M were shown. In Fig.
 412 4(a) a region with too high density of deposited sample is evidenced and large
 413 amorphous blobs are visible, likely resulting from coalescence of several

414 vesicles. Single niosomes were visible on the surface of blobs as well as on the
415 substrate. In order to obtain more accurate evaluation of vesicle size, regions
416 with deposited material were chosen as reported in Fig. 4(c), (e) and (g), where
417 several isolated niosomes with regular circular shape are clearly visible at
418 different magnification.

419 High resolution images of CG-NioP vesicles, as the one reported in Fig. 4(i),
420 show a niosomal granular surface. This is probably due to the convolution
421 between the real shape of the molecules of the bilayer and the AFM tip which is
422 spherical with nominal curvature radius less than 10 nm. In the analogous
423 images of the CG-NioP-M, e.g., that reported in Fig. 4(b), in addition to large
424 amorphous blobs and isolated vesicles, long filaments are visible, as evidenced
425 by the arrow in Fig. 4(b). These filaments are peculiar of mucin, in fact they are
426 not present in the sample CG-NioP. Images of the surface at different
427 magnification of CG-NioP-M, (Fig. 4(d), (f) and (h)) show that vesicles possess
428 regular circular shape and seem bigger than the corresponding samples without
429 mucin. Indeed, statistical analysis on the height of niosomes confirms the
430 increase of the mean vesicle height of CG-NioP-M respect to CG-NioP (i.e., from
431 20 ± 3 nm to 37 ± 3 nm). Analogously, the diameter increase of the vesicles on
432 the substrates is observed (i.e., from 290 ± 40 nm to 450 ± 20 nm). Moreover,
433 statistical analysis of D_{eq} of the niosomes evaluated using equation (2), and
434 reported in Table 1, indicates the same increase of CG-NioP-M respect to CG-
435 NioP (from 210 ± 30 nm to 320 ± 10 nm), in good agreement with results
436 obtained by the other techniques.

437



438
 439 **Figure 4.** Microscopic images ad different magnification using AFM: (a,c,e,f,g,i) CG-
 440 NioP and (b,d,f,h,l) CG-NioP-M. In the inset in (e) the sketch of a vesicle adherent to
 441 the substrate is reported.

442
 443 In this case, AFM technique, able to provide morphological and metrological
 444 information on nanocarriers; is also able to highlight the peculiar localization of mucin
 445 around the CG-NioP surface.

446
 447

448 **3.5. Brightfield microscopy**

449 To image and to measure low absorption contrast nanometer sized suspended
450 particles randomly moving in a solvent as a consequence of Brownian motion is a
451 terrific challenge for modern microscopy [1, 25]. In the case of biocompatible
452 particles, several constraints cannot be overcome: temperature and hydration could
453 not be controlled to slow down the particle dynamics, as the physico-chemical
454 environmental conditions strongly affect the particle character and behaviour;
455 analogously, the viscosity of the solvent cannot be altered, as the chemistry of the
456 niosomes is extremely sensitive.

457 At the same time, dynamics of nanometer sized bodies suspended in room
458 temperature water (or any other equally viscous liquid) is fast (the diffusion constant
459 could be estimated to be in the order of $10^{-12} \text{ m}^2\text{s}^{-1}$) and imaging time must be kept
460 as short as possible, a trade-off with a photon devouring technique as microscopy is.
461 On top of this, niosomes show a very low contrast with respect to the solvent, and
462 the floating particles would appear as very weak perturbations of the
463 homogeneous solvent background.


464 This set of restrictions was taken into account combining high spatial and temporal
465 resolutions provided by brightfield microscopy imaging recorded at high framerate
466 and high numerical aperture. The collected timestack movies show tiny spots, few
467 pixels wide, swirling for fraction of seconds in the focal plane. A crop of the time
468 sequence showing a particle entering and leaving the focal plane over a period
469 of 220 ms is shown in Fig. 5: panel a.

470


471

472

a



b



473

474 **Figure 5.** BFM experimental conditions of the images are as reported in section
475 2.2.9. Panel a: Time sequence montage of a 94x94 pixel crop timestack showing
476 a CG-NioP-M particle entering and leaving the focal plane. Two next images are
477 28 ms apart, while the integration time per image is 10 ms. Panel b: Size
478 distribution of CG-NioP and CG-NioP-M particles convoluted by the imaging
479 point spread function, as determined via the procedure described in the text.

480

481 Several similar events were recorded per every sample and following the
482 procedure described in the Materials and methods section, the full width half
483 maximum (FWHM) distributions of these spots was obtained. The corresponding
484 normal probability density functions for both the two niosome sets are depicted in
485 figure Fig. 5: panel b.

486 The average sizes for CG-NioP and CG-NioP-M are $(4.0 \pm 0.5) \cdot 10^2$ nm and
487 $(4.4 \pm 0.7) \cdot 10^2$ nm respectively. Of course, the FWHM determined by these
488 measurements does not correspond to the actual particle size, since the particle
489 projections on the focal plane are spread by the response of the imaging system
490 to a point object. In principle, it is possible to estimate the shape of this
491 response, namely the point spread function (PSF), but it is more convenient to
492 measure it experimentally. In the case of our optical arrangement, the PSF can
493 be approximated by a Lorentzian of 350 nm FWHM, and the deconvoluted
494 average particle diameters for the two niosomes are reported in table 1.


495

496 3.6. SAXS

497 To investigate the internal structure of niosomes and their interaction with mucin,
498 small angle X-ray scattering experiments on C, mucin and CG-NioP-M were carried
499 out. In Fig. 6, left panel, SAXS spectra of CG-NioP (purple) and mucin (green). The
500 intensity spectrum of mucin shows an intensity decay behavior characteristic for
501 polymer chains in a good solvent $I(q) \propto q^{-5/3}$. The spectrum of CG-NioP is dominated
502 by the features of the Span-based shell. The intensity peak at $q = 1.6 \text{ nm}^{-1}$ is sign of
503 an ordered structure. The q position corresponds to a characteristic distance $d =$
504 $2\pi/q$ between regularly arranged structures inside the niosomes. The presence of
505 this peak is observed in multilamellar liposomes or Tween-based niosomes [5] and

506 the corresponding characteristic distance is the repetition distance within the
 507 multilamellar shell, d = thickness of the lamella plus thickness of the interlamellar
 508 water layer. In the present Span 20 based system, the observed distance is quite
 509 small, $d = 3.8$ nm, and just twice the length of a Span 20 molecule (about 2 nm). This
 510 result indicates that the shell of the niosomes is a multi-layered structure made of
 511 several Span layers in close contact, without the presence of any interlamellar water
 512 layer. In the right panel the intensity spectrum corresponding to the mixed 1:1 (w/w)
 513 niosome:mucin system is shown (blue) together with the reconstructed spectrum
 514 (red) obtained by simple addition of the two components, CG-NioP and mucin . The
 515 peak position still stays at $q = 1.6 \text{ nm}^{-1}$ revealing no dramatic change in the niosome
 516 internal structure in presence of mucin. Rather the measured intensity spectrum
 517 deviates from the reconstructed one in the low q region, corresponding to the large
 518 distances. This behaviour is sign of an interaction between mucin and the external
 519 surface of niosomes resulting in the formation of larger complexes.

520
521



522
 523 **Figure 6.** Left panel. SAXS spectra of CG-NioP (purple dots) and mucin (green
 524 diamonds) The black line represents the intensity decay behaviour $I(q) \propto q^{-5/3}$. Right
 525 panel. CG-NioP-M intensity spectrum (blue dots) together with the reconstructed
 526 spectrum (red line) obtained by adding the contribution of the two (CG-NioP and
 527 mucin) components.


528

529 4. Conclusions

530 This study illustrates how these techniques can be used as valuable tools to
531 obtain quantitative and qualitative information about the chitosan coated
532 niosomes/mucin interaction. Dynamic light scattering (DLS), fluorimetric and
533 spectrophotometric assays, small-angle X-ray scattering (SAXS), atomic force
534 microscopy (AFM) and high speed brightfield microscopy (BFM) techniques
535 proved to be highly complementary and parallel. Therefore their synergic
536 combination allows for the characterization of a potential nanocarrier under
537 development from the design of the vector, to the evolution of the structure
538 upon encapsulation of the drug and interaction with biological barriers along
539 the administration route, like mucin (Fig. 7: panel a). Some techniques are able
540 to underline the increase of CG-NioP-M size respect to CG-NioP that confirm
541 the phenomena of interaction. Although, as expected by different techniques,
542 dimensions with different values are established, but the interaction
543 sample/mucin is demonstrated by physical chemical properties variations that
544 are, for all applied techniques always the same ($\cong 30\%$). According to all
545 techniques employed, the CG-Nio-P obtained from Span 20 surfactant shows
546 in vitro mucoadhesive properties and the interaction mucin-sample would
547 seem a superficial interaction, in fact, no change in the internal structure is
548 observed by SAXS or fluorometric measurements. Moreover, the vesicle
549 stability is maintained for 15 min, time of interaction with nasal mucosa after
550 intranasal administration (Fig. 7: panel b).

551 However, further studies are needed to verify, in vivo, the improved
552 bioavailability and the reduced drug clearance in nasal cavity respect to free
553 drug.

554 These techniques, able to investigate physical-chemical features of
555 nanocarriers and their mucin complexes, can be an essential tool to
556 understand and refine information on the potential interaction between
557 nanocarriers and biological environments, membranes and in vivo
558 compartments.



559

560 **Figure 7.** Panel a: Parameters evaluated by each technique to study niosome:
 561 mucin interaction. Panel b: Schematic representation of overall obtained results.

562

563

564 Acknowledgements

565 We thank ESRF for allocation of beamtime and Dr. A. Mariani for his
 566 assistance during SAXS experiments on ID02 beamline (ESRF). E.D.F. thanks
 567 BIOMETRA Department for in house support.

568 This work has been supported by Italian Ministry of Education, Universities
 569 and Research - Dipartimenti di Eccellenza - L. 232/2016 (Department of Drug
 570 Chemistry and Technologies, prof. Carafa and prof. Marianecci)

571

572

573 Founding

574 This research did not receive any specific grant from funding agencies in the
 575 public, commercial, or not-for-profit sectors.

576

577 References

578

579 [1] F. Rinaldi, L. Seguella, S. Gigli, P. Hanieh, E. Del Favero, L. Cantù, M.
 580 Pesce, G. Sarnelli, C. Marianecci, G. Esposito, inPentosomes: an innovative
 581 nose-to-brain pentamidine delivery blunts MPTP parkinsonism in mice, J.
 582 Control. Release 294 (2019) 17-26.

583 [2] D. Passeri, C. Dong, M. Reggente, L. Angeloni, M. Barteri, F.A.
 584 Scaramuzzo, F. De Angelis, F. Marinelli, F. Antonelli, F. Rinaldi, Magnetic

- 585 force microscopy: Quantitative issues in biomaterials, *Biomatter* 4 (2014)
586 e29507.
- 587 [3] P.P. Mondal, A. Diaspro, *Fundamentals of fluorescence microscopy: exploring life with light*, Springer Science & Business Media (2013).
- 588 [4] M. Pluta, P. Maksymilian, *Advanced light microscopy*, Elsevier Amsterdam
589 (1988).
- 590 [5] C. Marianecchi, L. Di Marzio, E. Del Favero, L. Cantù, P. Brocca, V.
591 Rondelli, F. Rinaldi, L. Dini, A. Serra, P. Decuzzi, Niosomes as drug
592 nanovectors: multiscale pH-dependent structural response, *Langmuir* 32
593 (2016) 1241-1249.
- 594 [6] E. Gavini, G. Rasso, L. Ferraro, A. Generosi, J.V. Rau, A. Brunetti, P.
595 Giunchedi, A. Dalpiaz, Influence of chitosan glutamate on the in vivo intranasal
596 absorption of rokitamycin from microspheres, *J. Pharm. Sci.* 100 (2011) 1488-
597 1502.
- 598 [7] L. Illum, P. Watts, A. Fisher, M. Hinchcliffe, H. Norbury, I. Jabbal-Gill, R.
599 Nankervis, S. Davis, Intranasal delivery of morphine, *J. Pharmacol. Exp. Ther.*
600 301 (2002) 391-400.
- 601 [8] L. Illum, Nasal drug delivery—recent developments and future prospects, *J.*
602 *Control. Release* 161 (2012) 254-263.
- 603 [9] E.B. Manaia, M.P. Abuçafy, B.G. Chiari-Andréo, B.L. Silva, J.A.O. Junior,
604 L.A. Chiavacci, Physicochemical characterization of drug nanocarriers, *Int. J.*
605 *Nanomed.* 12 (2017) 4991.
- 606 [10] F. Rinaldi, P.N. Hanieh, C. Marianecchi, M. Carafa, DLS Characterization
607 of Non-Ionic Surfactant Vesicles for Potential Nose to Brain Application,
608 *Nanosci. Nanometr.* 1 (2015) 8-14.
- 609 [11] F. Rinaldi, P.N. Hanieh, L.K.N. Chan, L. Angeloni, D. Passeri, M. Rossi,
610 J.T.-W. Wang, A. Imbriano, M. Carafa, C. Marianecchi, Chitosan Glutamate-
611 Coated Niosomes: A Proposal for Nose-to-Brain Delivery, *Pharmaceutics* 10
612 (2018) 38.
- 613 [12] C. Aguzzi, G. Sandri, C. Bonferoni, P. Cerezo, S. Rossi, F. Ferrari, C.
614 Caramella, C. Viseras, Solid state characterisation of silver sulfadiazine
615 loaded on montmorillonite/chitosan nanocomposite for wound healing, *Colloids*
616 *Surf. B Biointerfaces* 113 (2014) 152-157.

- 618 [13] S. Sennato, F. Bordi, C. Cametti, M. Diociaiuti, P. Malaspina, Charge
619 patch attraction and reentrant condensation in DNA–liposome complexes,
620 BBA-Biomembranes 1714 (2005) 11-24.
- 621 [14] P.T. Wong, S.H. Wang, S. Ciotti, P.E. Makidon, D.M. Smith, Y. Fan, C.F.
622 Schuler IV, J.R. Baker Jr, Formulation and characterization of nanoemulsion
623 intranasal adjuvants: effects of surfactant composition on mucoadhesion and
624 immunogenicity, Mol. Pharmaceut. 11 (2013) 531-544.
- 625 [15] A. Sosnik, J. das Neves, B. Sarmiento, Mucoadhesive polymers in the
626 design of nano-drug delivery systems for administration by non-parenteral
627 routes: a review, Prog. Polym. Sci. 39 (2014) 2030-2075.
- 628 [16] T. Klemetsrud, H. Jonassen, M. Hiorth, A.-L. Kjøniksen, G. Smistad,
629 Studies on pectin-coated liposomes and their interaction with mucin, Colloids
630 Surf. B Biointerfaces 103 (2013) 158-165.
- 631 [17] Y.A. Albarkah, R.J. Green, V.V. Khutoryanskiy, Probing the
632 Mucoadhesive Interactions Between Porcine Gastric Mucin and Some Water-
633 Soluble Polymers, Macromol. Biosci. 15 (2015) 1546-1553.
- 634 [18] E. McClean, L. McGrath, G. Archbold, Comparison of two fluorescent
635 probes for the measurement of erythrocyte membrane fluidity in renal dialysis
636 patients, Irish J. Med. Sci. 164 (1995) 289-292.
- 637 [19] K. Zachariasse, Microviscosity measurements in micelles and
638 phospholipids, Berich. Bunsen. Gesell. 82 (1978) 950-950.
- 639 [20] C. Ingallina, F. Rinaldi, A. Bogni, J. Ponti, D. Passeri, M. Reggente, M.
640 Rossi, A. Kinsner-Ovaskainen, D. Mehn, F. Rossi, Niosomal approach to brain
641 delivery: Development, characterization and in vitro toxicological studies, Int.
642 J. Pharmaceut. 511 (2016) 969-982.
- 643 [21] G. Sandri, S. Motta, M.C. Bonferoni, P. Brocca, S. Rossi, F. Ferrari, V.
644 Rondelli, L. Cantù, C. Caramella, E. Del Favero, Chitosan-coupled solid lipid
645 nanoparticles: tuning nanostructure and mucoadhesion, Eur. J. Pharm.
646 Biopharm. 110 (2017) 13-18.
- 647 [22] O. Teschke, E. De Souza, Liposome structure imaging by atomic force
648 microscopy: verification of improved liposome stability during adsorption of
649 multiple aggregated vesicles, Langmuir 18 (2002) 6513-6520.

650 [23] C.T. Rueden, J. Schindelin, M.C. Hiner, B.E. DeZonia, A.E. Walter, E.T.
651 Arena, K.W. Eliceiri, ImageJ2: ImageJ for the next generation of scientific
652 image data, BMC bioinformatics 18 (2017) 529.

653 [24] M.I. Adamczak, Ø.G. Martinsen, G. Smistad, M. Hiorth, Polymer coated
654 mucoadhesive liposomes intended for the management of xerostomia, Int. J.
655 Pharmaceut. 527 (2017) 72-78.

656 [25] D. Coglitore, S.P. Edwardson, P. Macko, E.A. Patterson, M. Whelan,
657 Transition from fractional to classical Stokes–Einstein behaviour in simple
658 fluids, Roy. Soc. Open Sci. 4 (2017) 170507.

659

Journal Pre-proof

Highlights

- Physical-chemical characterization of niosomes/mucin interaction.
- Different, non conventional and complementary techniques to perform analytical characterization.
- DLS, AFM, BFM, Spectrophotometric techniques.
- SAXS, Fluorimetric techniques.
- No change of internal niosomal structure, superficial mucin interaction.

Conflicts of Interest: The author declares no conflict of interest.

Journal Pre-proof